Scarica l'app Stockscreener
215.43
2.23%
4.70
Dopo l'orario di chiusura:
215.43
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BIIB Giù?
Forum
Previsione
Frazionamento azionario
Biogen Inc Borsa (BIIB) Ultime notizie
Alzheimer’s Disease Market Trends, Innovation, and Future Growth Outlook to 2036 – DelveInsight | Alpha Cognition, Biogen, Eisai, Eli Lilly, Otsuka Pharma, Lundbeck, Suven Life Sciences, Roche - Barchart.com
Multiple Sclerosis Market Outlook 2036: Growth Trends, Competitive Landscape, and Future Opportunities by 2034 – DelveInsight | Biogen, Immune Response BioPharma, ImCyse, Atara Bio, Emerald Health - Barchart.com
BIIB Maintained by HSBC -- Price Target Raised to $175 - GuruFocus
Biogen Inc. stock gains on fresh analyst upgrades and strong Q2 figures - ad-hoc-news.de
Stifel reiterates Biogen stock rating on immunology pipeline - Investing.com
Stifel reiterates Biogen stock rating on immunology pipeline By Investing.com - Investing.com Canada
Can Biogen (NASDAQ:BIIB) Stay Resilient As Inflation Rises? - Kalkine Media
Biogen at Wells Fargo healthcare conference: growth bets widen By Investing.com - Investing.com Canada
Biogen Inc. at Wells Fargo Healthcare Conference Transcript - GuruFocus
Learn Why The Bull Case For Biogen Stock Could Change Following Canada Reimbursement Backing - simplywall.st
Monoclonal Antibodies Market to Grow at 11.01% CAGR, Reaching USD 791.28 Billion by 2035 – SNS Insider - GlobeNewswire Inc.
Biogen Inc (BIIB) Shares Fall 3.8% -- What GF Score of 73 Tells Investors - GuruFocus
Biogen Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Dyne, Sarepta shares tumble as Novartis setback weighs on muscle disease drug developers - Reuters
Biogen Must Face Pharmacies' MS Drug Monopoly Suit - Law360
(BIIB) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Biogen stock heads into the open without fresh price data - ad-hoc-news.de
Biogen Inc. (BIIB) Investor Outlook: Navigating Growth in the Healthcare Sector with a Potential 7.26% Upside - DirectorsTalk Interviews
Biogen Inc at Bank of America Global Healthcare Conference Transcript - GuruFocus
Biogen Inc. stock holds near 12 month high on steady Q1 2026 growth - ad-hoc-news.de
BIIB Stock Price Prediction 2026-2027 | Biogen Forecast - 24/7 Wall St.
Biogen Inc. (BIIB) Peer Comparison – Compare with Others - Value Research
Eisai, Biogen Secure China's Nod for Self-Injection Version of Leqembi - marketscreener.com
Biogen (BIIB), Why Is Its Latest Update Drawing Fresh Attention? - simplywall.st
Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC) - Biogen
Stoke Therapeutics and Biogen Present Long-Term Clinical - globenewswire.com
Biogen (BIIB) awards 7,405 stock units to its top lawyer - Stock Titan
Biogen Is Repositioning Its Portfolio To Partly Offset Ongoing Revenue Declines - Morningstar
Piper Sandler raises Biogen stock price target on pipeline outlook - Investing.com
Eisai, Biogen Win China Approval for Leqembi Self-Injection - International Business Times
Price cut becomes the price of coverage for Alzheimer's drug lecanemab - Benefits and Pensions Monitor
Biogen (BIIB) FDA Approvals, PDUFA Dates & Drug Alerts 2026 $BIIB - MarketBeat
Biogen Inc. (BIIB) Key Financial Ratios – Valuation, Profitability & More - Value Research
Eisai and Biogen Announce China Approval of LEQEMBI SC-AI for Initiation Treatment of Early Alzheimer’s Disease - Quiver Quantitative
LEQEMBI® (lecanemab) Subcutaneous Formulation as an Initiation Treatment for Early Alzheimer’s Disease Approved in China - Biogen
Biogen (BIIB) Stock Could Be 48% Below Fair Value On New Dravet Data - Yahoo Finance
How Biogen’s (BIIB) At-Home LEQEMBI Injections Could Reframe the Alzheimer’s Treatment Investment Story - simplywall.st
Biogen Inc (BIIB) Shares Surge 3.1% -- What GF Score of 73 Tells Investors - GuruFocus
Biogen Inc. stock outperforms competitors on strong trading day - MarketWatch
Biogen gains as pipeline updates and fresh Street target hikes buoy sentiment - Quiver Quantitative
Biogen stock hits 52-week high at 222.86 USD By Investing.com - Investing.com Canada
Biogen stock hits 52-week high at 222.86 USD - Investing.com
A potential seizure treatment will be presented Sept. 9 by Stoke Therapeutics - Stock Titan
Biogen’s (BIIB) Immunology Bet Meets A Pricier Balance Sheet - Yahoo Finance
BIIB | Biogen Inc. Common Stock FinancialsRevenue Breakdown - Quiver Quantitative
Stoke, Biogen present 4-year zorevunersen data for Dravet syndrome - Investing.com
Stoke, Biogen Present 4-Year Dravet Syndrome Data at EEC | BIIB Stock News - Stock Titan
Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC) - Yahoo Finance
Eisai and Biogen Announce Canada’s Drug Agency Final Recommendation Supporting Public Reimbursement of LEQEMBI for Eligible Early Alzheimer’s Disease Patients - Quiver Quantitative
Canada’s Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement of LEQEMBI® (lecanemab) for Early Alzheimer’s Disease - Biogen
Final CDA-AMC Recommendation Brings Canadians with Early-Stage Alzheimer's Disease One Step Closer to Accessing LEQEMBI® (lecanemab) - PR Newswire Canada
Price to book forward of Biogen Inc. – NASDAQ:BIIB - TradingView
Biogen Inc. (BIIB) Stock Report: Analyst Ratings Signal Potential Upside Of Over 8% - DirectorsTalk Interviews
Biogen Inc. stock underperforms Friday when compared to competitors - MarketWatch
Why Is Biogen (BIIB) Up 6.5% Since Last Earnings Report? - Yahoo Finance
Will Biogen (BIIB) Make Early Alzheimer’s Treatment Easier At Home? - simplywall.st
RBC Capital raises Biogen stock price target on lupus drug potential - Investing.com
Eisai and Biogen Launch LEQEMBI IQLIK Subcutaneous Injection for Early Alzheimer’s Disease in the U.S. - Quiver Quantitative
Biogen Inc. (BIIB) Stock Analysis: Evaluating a Potential 8.67% Upside in the Healthcare Sector - DirectorsTalk Interviews
How Investors Are Reacting To Biogen (BIIB) Raising EPS Guidance On Late-Stage Drug Trial Milestones - simplywall.st
Biogen Expands Autoimmune Pipeline With New Graves’ Disease Trial - TipRanks
Biogen Inc. (NASDAQ:BIIB) Healthcare Momentum Draws Fresh Market Attention - Kalkine Media
What Biogen (BIIB)'s Higher Earnings Guidance and Late-Stage Pipeline Progress Means For Shareholders - Yahoo Finance
OVERSEA CHINESE BANKING Corp Ltd Purchases Shares of 18,867 Biogen Inc. $BIIB - MarketBeat
Wealthfront Advisers LLC Acquires Shares of 16,529 Biogen Inc. $BIIB - MarketBeat
OVERSEA CHINESE BANKING Corp Ltd Acquires Shares of 13,000 Biogen Inc. $BIIB - MarketBeat
66,365 Shares in Biogen Inc. $BIIB Bought by Danske Bank A S - MarketBeat
0.47%
1.72%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):